Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn’s Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned?

Key Points

• The study aims to evaluate the cost-effectiveness of biosimilar ustekinumab as a treatment for moderate to severe Crohn's disease in Spain.
• Conducted a cost-effectiveness analysis from the NHS perspective.
• Compared sequential treatment strategies including biosimilar ustekinumab and others.
• Evaluated drug acquisition costs and impact on patient access.
• Biosimilar ustekinumab positioned as cost-effective as a first-line treatment option.
• Alternative treatment sequences showed less cost-effectiveness compared to biosimilar ustekinumab with adalimumab.
• Lower drug acquisition costs may enhance patient access and management of Crohn's disease.